Related Experiment Video
Updated: May 20, 2026
10:55
Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
Targeted immunotherapy trials for idiopathic inflammatory myopathies
1Department of Neurology and Neuroscience, Weill Cornell Medical College/New York Presbyterian Hospital, 525 East 68th Street, New York, NY 10065-4885, USA. pstuebge@med.cornell.edu
Journal of Neurology
|July 4, 2012
Summary
Idiopathic inflammatory myopathies (IIM) present complex challenges due to varied immunopathogenesis and lack of standard treatments. This review explores targeted biological therapies for autoimmune muscle diseases, aiming for personalized treatment approaches.
Area of Science:
- Immunology
- Rheumatology
- Neurology
Background:
- Idiopathic inflammatory myopathies (IIM) are heterogeneous autoimmune muscle diseases with complex and variable immunopathogenesis.
- Current management lacks a universal consensus, leading to challenges in treating refractory cases.
- Advances in molecular biology and biologics offer new therapeutic avenues for autoimmune disorders.
Purpose of the Study:
- To review current biological therapeutics targeting humoral and cellular immunity in IIM.
- To discuss FDA-approved monoclonal antibodies and fusion proteins for immunological disorders.
- To envision a future of personalized, mechanism-tailored therapies for IIM.
Main Methods:
- Literature review of immunological components and biological targets in IIM.
- Analysis of FDA-approved biological agents (monoclonal antibodies, fusion proteins) for autoimmune diseases.
- Exploration of future directions in precision medicine for IIM.
Main Results:
- Identified key immune targets within humoral and cellular immunity relevant to IIM.
- Summarized the role of existing FDA-approved biological agents in managing immunological conditions.
- Highlighted the potential for targeted therapies based on individual immune profiles.
Conclusions:
- Biological therapeutics targeting specific immune pathways represent a promising frontier for IIM management.
- Personalized medicine, tailoring treatments to patient-specific immune mechanisms, is the future direction.
- Careful risk-benefit and cost analyses are crucial for implementing targeted therapies in IIM.
Related Concept Videos
01:27Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...